Sionna Therapeutics, Inc. (SION): Results of Operations and Financial Condition
Sionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Results of Operations and Financial Condition. Sionna Therapeutics Reports Second Quarter 2026 Financial Results PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026 Phase 1 trial evaluating NBD1 stabilizer SION-451 in pro
How this was made
The 30-second read
Why it matters
The key tradable elements are (1) updated financial burn and cash balance, and (2) reiterated timing for two clinical topline milestones in summer 2026. These can influence valuation multiples for pre-data biotech risk and expectations for upcoming catalysts.
Market read
For traders, the filing provides a near-term catalyst calendar (summer 2026 topline) plus a cash runway update, which can affect positioning ahead of trial readouts.
What to watch
Traders may over-weight “on track” language; the market will likely demand concrete sweat-chloride or safety signals at the upcoming topline windows rather than execution statements.
Sionna Therapeutics Reports Second Quarter 2026 Financial Results
Clinical programs remained on track for topline data in summer of 2026 and the company expects its cash position to fund operations into 2028, while research and development expense, general and administrative expense, operating loss and net loss were higher than the comparable 2025 quarter.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended June 30, 2026GAAP | $21.9 million | – | – |
| General and administrative expenses, three months ended June 30, 2026GAAP | $10.6 million | – | – |
| Total operating expenses, three months ended June 30, 2026GAAP | 32,470 (In thousands) | – | – |
| Loss from operations, three months ended June 30, 2026GAAP | (32,470) (In thousands) | – | – |
| Interest income, three months ended June 30, 2026GAAP | 2,587 (In thousands) | – | – |
| Other income (expense), net, three months ended June 30, 2026GAAP | (3) (In thousands) | – | – |
| Total other income, three months ended June 30, 2026GAAP | 2,584 (In thousands) | – | – |
| Net loss, three months ended June 30, 2026GAAP | $29.9 million | – | – |
| Net loss per share, basic and diluted, three months ended June 30, 2026GAAP | $ (0.66) | – | – |
| Weighted-average common shares outstanding, basic and diluted, three months ended June 30, 2026GAAP | 45,148,971 | – | – |
| Research and development expenses, six months ended June 30, 2026GAAP | 40,827 (In thousands) | – | – |
| General and administrative expenses, six months ended June 30, 2026GAAP | 21,242 (In thousands) | – | – |
| Total operating expenses, six months ended June 30, 2026GAAP | 62,069 (In thousands) | – | – |
| Loss from operations, six months ended June 30, 2026GAAP | (62,069) (In thousands) | – | – |
| Interest income, six months ended June 30, 2026GAAP | 5,407 (In thousands) | – | – |
| Other income (expense), net, six months ended June 30, 2026GAAP | (3) (In thousands) | – | – |
| Total other income, six months ended June 30, 2026GAAP | 5,404 (In thousands) | – | – |
| Net loss, six months ended June 30, 2026GAAP | (56,665) (In thousands) | – | – |
| Net loss per share, basic and diluted, six months ended June 30, 2026GAAP | $ (1.25) | – | – |
| Weighted-average common shares outstanding, basic and diluted, six months ended June 30, 2026GAAP | 45,306,105 | – | – |
into 2028 outlook
- NoteSionna expects its current cash position to fund operations into 2028.
- NoteTopline data from the PreciSION CF Phase 2a proof-of-concept trial are on track for this summer.
- NoteTopline data from the Phase 1 dual combination trial are on track for this summer.
What drove it
- Research and development expense increases were mainly driven by development expenses supporting advancement of Sionna’s clinical pipeline and personnel-related costs, including stock-based compensation expenses.
- General and administrative expense increases were primarily due to personnel-related costs, including stock-based compensation expenses, supporting continued growth and operational activities.
- The PreciSION CF Phase 2a proof-of-concept trial is evaluating SION-719 as an add-on to standard of care in CF participants.
- The Phase 1 trial is evaluating SION-451 in proprietary dual combinations with SION-2222 and SION-109 in healthy volunteers.
Concerns
- The company reported a net loss of $29.9 million for the second quarter of 2026, compared to a net loss of $18.1 million for the second quarter of 2025.
- Loss from operations was (32,470) (In thousands) for the three months ended June 30, 2026, compared to (21,906) (In thousands) for the comparable 2025 period.
- Interest income was 2,587 (In thousands) for the three months ended June 30, 2026, compared to 3,667 (In thousands) for the comparable 2025 period.
- Clinical results from the Phase 2a and Phase 1 trials have not yet been reported; both are expected in summer of 2026.
What to watch
- Topline data from the PreciSION CF Phase 2a proof-of-concept trial of SION-719 as an add-on to standard of care.
- Topline data from the Phase 1 dual combination trial of SION-451 with SION-2222 and with SION-109.
- Whether trial results demonstrate safety, tolerability, pharmacokinetics and change in CFTR function as measured by sweat chloride levels in the PreciSION CF trial.
- Execution against the stated expectation that the current cash position will fund operations into 2028.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities: $268.3 million as of June 30, 2026.
- Cash, cash equivalents, and marketable securities: $ 268,253 (In thousands) as of June 30, 2026, compared to $ 310,302 (In thousands) as of December 31, 2025.
- Working capital: 205,348 (In thousands) as of June 30, 2026, compared to 229,707 (In thousands) as of December 31, 2025.
- Total assets: 283,249 (In thousands) as of June 30, 2026, compared to 325,953 (In thousands) as of December 31, 2025.
- Total stockholders’ equity: 265,775 (In thousands) as of June 30, 2026, compared to 306,833 (In thousands) as of December 31, 2025.
Analysis
Sionna remained a clinical-stage company in the second quarter of 2026, with no revenue reported in the filing and financial performance defined by research, clinical development and corporate investment. Research and development expenses were $21.9 million, compared with $15.4 million in the second quarter of 2025. The company attributed the increase mainly to clinical-pipeline development expenses and personnel-related costs, including stock-based compensation expenses. General and administrative expenses were $10.6 million, compared with $6.5 million, primarily reflecting personnel-related costs including stock-based compensation.
The higher expense base was reflected in a $29.9 million net loss, compared with a net loss of $18.1 million in the comparable 2025 quarter. Loss from operations was (32,470) (In thousands), compared with (21,906) (In thousands). Interest income was 2,587 (In thousands), compared with 3,667 (In thousands), while total other income was 2,584 (In thousands), compared with 3,838 (In thousands). Net loss per share, basic and diluted, was $ (0.66), compared with $ (0.41).
The principal operating milestones are clinical. Enrollment in the PreciSION CF Phase 2a proof-of-concept trial of SION-719 was completed in April 2026, and topline data remain on track for summer of 2026. The company also said topline data from its Phase 1 trial of SION-451 in proprietary dual combinations with SION-2222 and SION-109 remain on track for summer of 2026. The Phase 2a trial is assessing safety, tolerability, pharmacokinetics and change in CFTR function measured by sweat chloride levels.
Liquidity remains the key financial support for the development plan. Cash, cash equivalents and marketable securities totaled $268.3 million as of June 30, 2026, and Sionna expects its current cash position to fund operations into 2028. The selected balance sheet data showed cash, cash equivalents and marketable securities of $ 268,253 (In thousands), versus $ 310,302 (In thousands) as of December 31, 2025, alongside lower working capital, total assets and total stockholders’ equity. No capital-return activity, debt balance, operating cash flow or free cash flow was disclosed in the release.
Management, verbatim
We continued to advance our clinical NBD1 stabilizer programs during the second quarter as we approach two important clinical milestones this summer. We remain focused on execution and delivering topline data from both our Phase 2a proof-of-concept trial and our Phase 1 dual combination trial. Together, these studies have the potential to further validate our core belief that directly stabilizing NBD1 is central to restoring CFTR function and transforming the treatment paradigm for people living with cystic fibrosis.
Mike Cloonan, President and Chief Executive Officer of Sionna
Not in the filing
stated, not guessed- Revenue and revenue comparisons were not reported.
- Revenue by segment was not reported.
- Gross profit and gross margin were not reported.
- Operating income was not reported; the filing reported loss from operations.
- Non-GAAP financial measures were not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Debt was not reported.
- Share repurchases and dividends were not reported.
- Tax expense, tax rate and guidance for tax rate were not reported.
- Prior-quarter comparisons for reported income-statement metrics were not reported.
- Percentage year-over-year and quarter-over-quarter changes for reported metrics were not reported.
- Financial revenue, gross-margin, operating-expense or tax-rate guidance was not reported.
- Prior outlook was not provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and a business update for Sionna’s NBD1 stabilizer programs in cystic fibrosis.
Ticker impact
Sionna reported Q2 2026 results and reiterated that Phase 2a SION-719 and Phase 1 dual-combo SION-451 topline data are on track for summer 2026.
Moderate near-term sensitivity to any subsequent trial readouts; otherwise likely to trade on biotech risk sentiment and cash-runway expectations.
The article is a primary SEC 8-K with financials, cash balance ($268.3M), and explicit timing guidance for two topline milestones in summer 2026, but it does not provide new efficacy/safety results.
Market effects
Adds incremental datapoint on NBD1-stabilizer CF drug development timelines, relevant to CF biotech sentiment but not a sector-wide reset.
Limited, as the disclosure is company-specific and not tied to a regional macro event.
Low; CF pipeline updates are globally relevant to the niche but do not indicate regulatory or competitive shocks.
Counterpoint
Cash runway into 2028 reduces immediate dilution risk, but the company still reports rising operating costs and no new clinical efficacy data, which can cap upside.
Key entities
- companySionna Therapeutics, Inc.
Clinical-stage CF biopharmaceutical company reporting Q2 2026 results and reiterating summer 2026 topline timelines.
- clinical_programSION-719 (NBD1 stabilizer)
PreciSION CF Phase 2a POC trial add-on to standard of care; topline data expected summer 2026.
- clinical_programSION-451 (NBD1 stabilizer)
Phase 1 dual combination trial in healthy volunteers with SION-2222 and SION-109; topline data expected summer 2026.
